Research Paper Volume 14, Issue 14 pp 5768—5782

Identification of the ferroptosis-related ceRNA network related to prognosis and tumor immunity for gastric cancer

Zhiping Xiang1, , Xingguo Zhou1, , Geofrey Mahiki Mranda1, , Ying Xue1, , Yu Wang1, , Tian Wei1, , Junjian Liu1, , Yinlu Ding1, ,

  • 1 Department of Gastrointestinal Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China

Received: March 22, 2022       Accepted: July 5, 2022       Published: July 14, 2022
How to Cite

Copyright: © 2022 Xiang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Gastric cancer (GC) is a highly invasive course and has a very poor prognosis. Because there are no obvious symptoms in the early stage, most patients with GC are diagnosed in the late stage. The effective diagnosis, prognosis biomarkers and treatment targets of GC can solve this problem to a great extent. Although researchers have done a lot of research on GC in recent years, the relationship between the competing endogenous RNA (ceRNA) network of ferroptosis-related genes and the GC remains to be explored. Therefore, the research done in this paper has become particularly important. Download the expression data and clinical survival data about stomach adenocarcinoma from UCSC Xena and The Cancer Genome Atlas (TCGA) platform. Using bioinformatics tools to screen lncRNAs, miRNAs and mRNAs that are differentially expressed in GC samples and normal samples and related to the prognosis of GC. Then, screening lncRNAs, miRNAs and mRNAs with targeted relationships from the Starbase database. Subsequently, correlation analysis and survival analysis were carried out respectively. Finally, we get a ceRNA network related to the prognosis of GC patients. Cell experiments confirmed the results obtained by bioinformatics. This is critical for the discovery of the diagnosis, prognosis biomarkers and treatment targets.


ceRNA: Competing endogenous RNA; CNV: Copy number variation; COR: Correlation coefficient; FC: Fold change; FDR: False discovery rate; GC: Gastric cancer; GSH: Glutathione; lncRNA: Long non-coding RNA; miRNA: MicroRNA; MRE: MicroRNA response element; OA: Osteoarthritis; OS: Overall survival rate; ROS: Reactive oxygen species; siRNA: Small interfering RNA; STAD: Stomach adenocarcinoma; TCGA: The cancer genome atlas; TILs: Tumor-infiltrating lymphocytes; TIMER: Tumor immune estimation resource; TME: Tumor microenvironment.